Enhanced Antitumor Efficacy by a Cascade of Reactive Oxygen Species Generation and Drug Release

Wang, Sheng; Yu, Guocan; Wang, Zhantong; Jacobson, Orit; Lin, Lisen; Yang, Weijing; Deng, Hongzhang; He, Zhimei; Liu, Yuan; Chen, Zhi‐Yi; Chen, Xiaoyuan

doi:10.1002/ange.201908997

Cited by 55 publications

(26 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies show opposite results, in which BLP was cytotoxic due to the high production of reactive oxygen species and induced apoptosis in MDA-MB-231 human breast cancer cells (Zada et al, 2019). In another study, BLP was activated by reactive oxygen species to generate hydrogen, converted into hydroxyl radicals, which increased its anti-tumor cytotoxic activity (Wang et al, 2019).…”

Section: Resultsmentioning

confidence: 96%

“…The experimental model used in G2 to simulate ischemia was a sealed chamber, similar to Zhu et al, 2015, which created quasi-anaerobic conditions with an oxygen concentration of less than 1%. Reactive oxygen species can be used as a therapeutic agent and as a stimulus to achieve greater efficacy of antitumor drugs (Wang et al, 2019). Oxidative stress, through the process of ischemia and reperfusion, can be induced experimentally, improving the knowledge of mechanisms of action and possible cytotoxicity of antioxidant substances.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cytotoxicity assessment of beta-lapachone in endothelial cells

Gonçalves

Cruz

Nepomuceno

et al. 2021

Acta Sci. Biol. Sci.

View full text Add to dashboard Cite

The selective activity of an antineoplastic drug is related to its ability to promote cytotoxic action on tumor cells and preserve the integrity of non-neoplastic cells. Beta-lapachone is extracted from the sawdust of Ipe wood, a thick bark tree from the Ipe wood found in the Brazilian Cerrado biome. This study aimed to evaluate the cytotoxic action of beta-lapachone in an endothelial cell line. The EA.hy926 cells were seeded in two groups, G1 and G2, cultured and exposed to beta-lapachone at concentrations of 0.0, 0.01, 0.03, 0.1, 0.3, 1 and 3 μM for 24 hours. G1 remained under normal cultivation conditions and G2 was subjected to oxidative stress through an ischemia and reperfusion assay, in a deoxygenated sealed chamber. The cytotoxicity assay was performed using the tetrazolium reduction method. In G1, the cytotoxicity ranged from 0.0 to 10.0%; and in G2 between 0.0 and 6.3%. No statistically significant difference was observed between the obtained values. Moreover, we found no cytotoxic action of beta-lapachone on endothelial cells, and the results point out that the drug might have preserved the cell’s integrity against oxidative stress under the conditions of this experiment. This promising result suggests the possibility of beta-lapachone as a chemotherapy drug with selective activity.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Cytotoxicity assessment of beta-lapachone in endothelial cells

Gonçalves

Cruz

Nepomuceno

et al. 2021

Acta Sci. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…As H 2 O 2 , the substrate of CDT, is often present in tumor regions at higher levels than in normal tissues, CDT is considered as a highly specific therapeutic strategy with low systemic toxicity. To date, many metal‐containing NPs (Bao et al, 2020; Han et al, 2020; D. Wang, Gao, et al, 2020a), including MOFs (Ni et al, 2020; Z. Shen, Liu, Li, et al, 2018b; Xue et al, 2019; Zou et al, 2018), MnO 2 NPs (S. Wang, Yu, et al, 2019d), and iron‐incorporated NPs (S. Wang, Yang, et al, 2019c), have been developed for CDT. Interestingly, mounting evidence suggests that CDT can efficiently improve the therapeutic outcome of chemodrugs and even has the potential to combat MDR, mainly due to its ability to induce severe cellular oxidative stress (X. Wang, Zhong, et al, 2020c).…”

Section: Nanostrategy‐mediated Combination Therapy For Mdr Reversalmentioning

confidence: 99%

Nanomedicines for combating multidrug resistance of cancer

Zhu

Jia

Duan

et al. 2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Chemotherapy typically involves the use of specific chemodrugs to inhibit the proliferation of cancer cells, but the frequent emergence of a variety of multidrug‐resistant cancer cells poses a tremendous threat to our combat against cancer. The fundamental causes of multidrug resistance (MDR) have been studied for decades, and can be generally classified into two types: one is associated with the activation of diverse drug efflux pumps, which are responsible for translocating intracellular drug molecules out of the cells; the other is linked with some non‐efflux pump‐related mechanisms, such as antiapoptotic defense, enhanced DNA repair ability, and powerful antioxidant systems. To overcome MDR, intense efforts have been made to develop synergistic therapeutic strategies by introducing MDR inhibitors or combining chemotherapy with other therapeutic modalities, such as phototherapy, gene therapy, and gas therapy, in the hope that the drug‐resistant cells can be sensitized toward chemotherapeutics. In particular, nanotechnology‐based drug delivery platforms have shown the potential to integrate multiple therapeutic agents into one system. In this review, the focus was on the recent development of nanostrategies aiming to enhance the efficiency of chemotherapy and overcome the MDR of cancer in a synergistic manner. Different combinatorial strategies are introduced in detail and the advantages as well as underlying mechanisms of why these strategies can counteract MDR are discussed. This review is expected to shed new light on the design of advanced nanomedicines from the angle of materials and to deepen our understanding of MDR for the development of more effective anticancer strategies. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

“…Then Ce6 was conjugated on the BSA to play roles in FL imaging and PDT while FeS 2 was responsible for PA/MR imaging and PTT. There are many Feinvolved nanomaterials for biomedical applications, one important reason lies in that they can induce Fenton reaction where highly toxic hydroxyl radicals are produced to kill cancer cells (S. Wang, Yu, et al, 2019;C. Zhang, Bu, et al, 2016).…”

Section: Bsa-based Nanoplatformmentioning

confidence: 99%

Protein‐based nanoplatforms for tumor imaging and therapy

Liang

Chen

2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Cancer is one of the leading causes of death all over the world. The development of nanoplatform provides a promising strategy for the diagnosis and treatment of cancer. As the foundation of the nanoplatform, the composition of nanocarrier decides the basic properties. Protein exists in all kinds of life and participates in any life activities, having great potentials to serve as a nanocarrier because of its excellent biocompatibility, abundance of functional groups, and inherent biological activity. As a result, protein‐based nanoplatforms have evoked extensive interests for tumor imaging and therapy. This review presents the latest progresses on the advancement of protein‐based nanoplatforms, introducing the most common protein nanocarriers (such as human/bovine serum albumin, ferritin, human transferrin) thoroughly including their physiochemical properties and specific applications. Also, other kinds of protein are briefly involved. Finally, the prospects and challenges of the development of protein‐based nanoplatforms are summarized. This article is categorized under: Biology‐Inspired Nanomaterials > Protein and Virus‐Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Enhanced Antitumor Efficacy by a Cascade of Reactive Oxygen Species Generation and Drug Release

Cited by 55 publications

References 77 publications

Cytotoxicity assessment of beta-lapachone in endothelial cells

Cytotoxicity assessment of beta-lapachone in endothelial cells

Nanomedicines for combating multidrug resistance of cancer

Protein‐based nanoplatforms for tumor imaging and therapy

Contact Info

Product

Resources

About